| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6818795caa359564ea6dda2c241da60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b91fd27a0829f9e9c051b2a8b382a81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed13822602be84e5c820b55258466460
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1288ad117e48b14ee2f12138137bf120
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe794d81001d258ba4c04241250e292e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d7a0c49e4b9499de007d9dc1d6728bc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4716
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-105831 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-96 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-96 |
| filingDate |
2007-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4667fa1371e5d28b9c549d07f6d6ebb0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39815cdd7628c9e8cab017f50676c7cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11ae8f3a995df4d05bdb99592407cba3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e1305f6638379378c97a769ed68b7c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37bfad690f66209bb7f349d63f6ee5a2 |
| publicationDate |
2007-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007118983-A1 |
| titleOfInvention |
C4d/c4b standard for quantitative flow cytometry of humoral transplant rejection |
| abstract |
The invention concerns an internal standard used to quantitative analysis of the risk of humoral (i.e. vascular) transplant rejection. The internal standard consists of a stable composition of the C4d complement bound to a carrier consisting of erythrocytes or microparticles. The invention also concerns a method for analyzing in vitro the risk of humoral organ transplant rejection, which consists in determining the amount of component of C4d component fixed on the erythrocytes contained in a blood sample from a patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014006063-A2 |
| priorityDate |
2006-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |